SWOG clinical trial number
S1800A

A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)

100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Abbreviated Title
LUNGMAP S1800A: Non-Match Immunotherapy Combination Sub-Study
Status Notes
S1800A closed to accrual November 16, 2020.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Activated
05/17/2019
Closed
11/16/2020
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

LungMAP
Lung Cancer

Treatment

MK-3475 Ramucirumab

Other Study Materials

Other Clinical Trials

S2414
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
1% Accrual
Accrual
1%
Open
Phase
CTSU/NRG-LU007
SWOG Clinical Trial Number